75 Results for "

CRC cells

" in MedChemExpress (MCE) Product Catalog:
Products (75)

75 Results for "CRC cells" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-136541
CAS No.: 1144043-83-3
Purity:  99.80%
Synonyms: Wnt pathway inhibitor 2
Target:  

Wnt Apoptosis

Research Areas:  

Cancer

YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N3389
CAS No.: 66056-19-7
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC50 of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1201
CAS No.: 84211-54-1
Target:  

Somatostatin Receptor

Research Areas:  

Cancer

Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-107460
CAS No.: 1198408-78-4
Purity:  ≥99.0%
Target:  

Ephrin Receptor

Research Areas:  

Cancer

LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N3001
CAS No.: 957-66-4
Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits VEGF expression and tyrosine phosphorylation of VEGFR2. Isolinderalactone decreases viability and induces apoptosis in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-Q51222
CAS No.: 100264-64-0
Research Areas:  

Cancer

ZINC110492 is a selective ligand of CS-ΔEx4 (a splicing isoform of citrate synthase (CS)). ZINC110492 does not bind to CS full-length (CS-FL). ZINC110492 inhibits colorectal cancer (CRC) cell growth in cells overexpressing CS-ΔEx4 with an IC50 of 7.840 µM. ZINC110492 significantly decreases both citrate and 2-hydroxyglutarate (2-HG) levels in the CS-ΔEx4-overexpressing SW1116 cells .
loading...
    loading...
Cat. No.: HY-P99406
CAS No.: 2213450-26-9
Synonyms: MCLA 158

Target:  

EGFR

Research Areas:  

Cancer

Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
loading...
    loading...
Cat. No.: HY-147245
CAS No.: 1858179-75-5
Purity:  98.49%
Synonyms: STP1002
Target:  

PARP

Research Areas:  

Cancer

Basroparib (STP1002) is a selective, orally active inhibitor of tankyrase (TNKS1/TNKS2) with IC50 of 29.94 nM and 3.68 nM for TNKS1 and TNKS2, respectively. Basroparib has an IC50 of >10 μM for PARP1. Basroparib binds to TNKS, stabilizes AXIN1/2 proteins, blocks Wnt/β-catenin signaling pathway, inhibits tumor cell proliferation and induces apoptosis, while reducing cancer stem cell properties. Basroparib can be used in colorectal cancer (CRC) studies with KRAS mutations (such as G12V/G12D) to overcome acquired resistance to MEK inhibitors. STP1002 has synergistic antitumor activity with MEK inhibitors .
loading...
    loading...
Cat. No.: HY-P10944
CAS No.: 3076330-05-4
Synonyms: NNS309
Target:  

FAP

Research Areas:  

Inflammation/Immunology Cancer

Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with 68Ga and 177Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .
loading...
    loading...
Cat. No.: HY-156112
CAS No.: 2055494-50-1
Purity:  99.78%
Target:  

Ser/Thr Protease

Research Areas:  

Cancer

LM2I is a derivative of Spinosyn A (SPA). LM2I is argininosuccinate synthase (ASS1) enzyme activator, and tumor inhibitor that directly interact with ASS1. LM2I has significant antiproliferative activity in seven colorectal cancer cell-lines and xenograft tumors of colorectal cancer. LM2I inhibits colorectal cancer cell growth via the EGFR pathway .
loading...
    loading...
Cat. No.: HY-175751
CAS No.: 3063346-83-5
Target:  

mTOR

Research Areas:  

Cancer

LRK-4189 is an orally active PIP4K2C (a regulator of mTOR complex) degrader and type 1 immune activator. LRK-4189 induces the degradation of the lipid kinase PIP4K2C. LRK-4189 triggers the interferon signaling pathway in microsatellite-stable (MSS) colorectal cancer cells, activates immunogenic tumor killing, and induces endogenous cell death. LRK-4189 sensitizes microsatellite-stable colorectal cancer tumors to NK cell killing and dendritic cell phagocytosis. LRK-4189 can be used for the research of microsatellite-stable colorectal cancer .
loading...
    loading...
Cat. No.: HY-116572A
CAS No.: 792927-06-1
Purity:  99.91%
Research Areas:  

Cancer

TASIN-1 is a selective inhibitor of truncated APC TR (adenomatous polyposis coli gene) that exerts cytotoxic effects by inhibiting cholesterol biosynthesis. TASIN-1 specifically targets colorectal cancer (CRC) cells carrying APC truncated mutations, while having no significant toxicity to wild-type APC cells. TASIN-1 exerts cytotoxic effects by targeting Emopamil binding protein (EBP) to inhibit cholesterol biosynthesis, triggering endoplasmic reticulum (ER) stress, reactive oxygen species (ROS) generation, and JNK-mediated apoptosis, and inhibiting Akt survival signaling. TASIN-1 can be used to prevent and intervene in APC mutant colorectal cancer .
loading...
    loading...
Cat. No.: HY-107425A
CAS No.: 1797406-72-4
Synonyms: MZP-42
Research Areas:  

Cancer

cis-MZ 1 (MZP-42) serves as a negative control for BRD4-targeted PROTAC MZ 1 (HY-107425). cis-MZ 1 can be used in colorectal cancer-related research .
loading...
    loading...
Cat. No.: HY-110390
CAS No.: 263890-70-6
Purity:  99.61%
GR148672X is an inhibitor of carboxylesterase 1 (CES1) and hepatic microsomal triglyceride hydrolase (TGH). GR148672X blocks the catalytic activity of CES1, impairs the functions of triglyceride and cholesteryl ester lipase, reduces triglyceride mobilization and secretion, and decreases apolipoprotein B-100 secretion in primary rat hepatocytes. Under low-glucose conditions, GR148672X inhibits the survival of colorectal cancer cells by reducing free fatty acid availability, inducing toxic triglyceride accumulation, ROS production, mitochondrial damage, ferroptosis and apoptosis. GR148672X can be used in studies related to colorectal cancer and atherosclerosis .
loading...
    loading...
Cat. No.: HY-148660
CAS No.: 2361332-90-1
Purity:  99.75%
Research Areas:  

Cancer

SFI003 is a SRSF3 inhibitor that drives CRC cell apoptosis via the SRSF3/DHCR24/ROS axis and exhibits potent antitumor effects both in vitro and in vivo .
loading...
    loading...
Cat. No.: HY-139065
CAS No.: 2254434-33-6
Purity:  99.87%
Target:  

Apoptosis

Research Areas:  

Cancer

AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research .
loading...
    loading...
Cat. No.: HY-114977
CAS No.: 108605-70-5
Purity:  99.20%
Avenanthramide A is an orally active phytoalexin that targets the RNA helicase DDX3 with a KD of 8.8 μM. Avenanthramide A induces mitochondrial swelling and increased ROS production, and triggers apoptosis in CRC cells. Avenanthramide A inhibits smooth muscle cell proliferation and enhances nitric oxide production. Avenanthramide A can be used in research on colorectal cancer and atherosclerosis .
loading...
    loading...
Cat. No.: HY-176806
CAS No.: 606967-53-7
Synonyms: Doxorubicin-LNAA-Boc
Target:  

Drug Derivative

Research Areas:  

Cancer

Legubicin (Doxorubicin-LNAA-Boc) is a novel conjugate of Doxorubicin (HY-15142A) and a Legumain-cleavable peptide linker. Legubicin is activated by Legumain to release leucine-doxorubicin while sparing normal tissues. Legubicin inhibits tumor cell growth and reduces DNA binding in non-legumain expressing cells. Legubicin completely arrests tumor growth in mice bearing CT26 tumors. Legubicin can be used for the study of colon carcinoma (CRC) .
loading...
    loading...
Cat. No.: HY-P99406A

Target:  

EGFR

Research Areas:  

Cancer

Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5 monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucosyl loss enhances the ADCC effect of the antibody. Petosemtamab (FUT8-KO) leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab (FUT8-KO) can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC) .
loading...
    loading...
Cat. No.: HY-139621
CAS No.: 2916559-62-9
Research Areas:  

Cancer

Colibactin 742 is a covalently binding DNA-damaging agent targeting DNA, with an IC50 of 5.2 μM against human cervical cancer cells (HeLa). Colibactin 742 covalently binds to DNA, forming interstrand crosslinks (ICLs), activating the Fanconi anemia DNA repair pathway, inducing γH2AX and FANCD2 foci formation and cell cycle arrest, while exacerbating mismatch repair deficiency (MMRd)-related mutations. Colibactin 742 can mimic the genotoxicity of natural Colibactin while avoiding its instability, and is mainly used in colorectal cancer (CRC) related research, including microbial tumorigenesis mechanisms, DNA damage repair pathways, and mutation signature analysis .
loading...
    loading...